Table 4.
Multivariate analysis of clinicopathological characteristics associated with BCSS and OS.
| Characteristics | BCSS | OS | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | HR | 95% CI | P-value | |
| T stage | .041 | .016 | ||||
| T1 | 1 | 1 | ||||
| T2 | 2.204 | 0.928-5.234 | .073 | 1.867 | 0.875-3.987 | .107 |
| T3 + T4 | 3.537 | 1.318-9.494 | .012 | 3.405 | 1.428-8.121 | .006 |
| N stage | <.001 | <.001 | ||||
| N0 | 1 | 1 | ||||
| N1 | 1.882 | 0.801-4.423 | .147 | 1.566 | 0.745-3.291 | .236 |
| N2 + N3 | 11.155 | 4.865-25.576 | <.001 | 8.661 | 4.233-17.721 | <.001 |
| HER2 status | .003 | |||||
| 0 | 1 | |||||
| Low | 0.449 | 0.263-0.767 | ||||
| Type of surgery | .110 | .220 | ||||
| Breast-conserving | 1 | 1 | ||||
| Mastectomy | 2.079 | 0.847-5.106 | 1.607 | 0.753-3.431 | ||
| Radiation therapy | .202 | .120 | ||||
| No | 1 | 1 | ||||
| Yes | 1.621 | 0.771-3.408 | 1.684 | 0.874-3.244 | ||
Abbreviations: BCSS: breast cancer-specific survival; OS: overall survival; HER2: human epidermal growth factor receptor 2; IHC: immunohistochemistry.